Cargando…

Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment

BACKGROUND: Dedifferentiated chondrosarcomas (CS) are a high-grade variant of CS that confers a 5-year survival of around 10–24%. Dedifferentiated CS arising from the pelvis confers an even worse prognosis. QUESTIONS: (1) What is the prognosis of patients with dedifferentiated CS of the pelvis? (2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lex, Johnathan R., Evans, Scott, Stevenson, Jonathan D., Parry, Michael, Jeys, Lee M., Grimer, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293503/
https://www.ncbi.nlm.nih.gov/pubmed/30559960
http://dx.doi.org/10.1186/s13569-018-0110-1
_version_ 1783380546428076032
author Lex, Johnathan R.
Evans, Scott
Stevenson, Jonathan D.
Parry, Michael
Jeys, Lee M.
Grimer, Robert J.
author_facet Lex, Johnathan R.
Evans, Scott
Stevenson, Jonathan D.
Parry, Michael
Jeys, Lee M.
Grimer, Robert J.
author_sort Lex, Johnathan R.
collection PubMed
description BACKGROUND: Dedifferentiated chondrosarcomas (CS) are a high-grade variant of CS that confers a 5-year survival of around 10–24%. Dedifferentiated CS arising from the pelvis confers an even worse prognosis. QUESTIONS: (1) What is the prognosis of patients with dedifferentiated CS of the pelvis? (2) Do wide margins or type of surgical intervention influence outcome? (3) Does the use of adjuvant therapy affect outcome? METHODS: Patients were retrospectively reviewed from a prospectively collated musculoskeletal oncology database from 1995 to 2016. Thirty-one cases of dedifferentiated CS arising from the pelvis were included. Wide margins were defined as greater than 4 mm. The mean age was 55.6 years (range 33 to 76 years) and there were 19 males (61.3%) and 12 females (38.7%). RESULTS: The disease presented at a locally or systemically advanced stage in 13 patients (41.9%). Eighteen patients (58.1%) underwent surgery with curative intent. Overall survival at 12 months was 15.4% for patients treated with palliative intent and 50% for those treated with surgery. In the surgical group, there were higher rates of disease-free survival in patients who underwent hindquarter amputation and those who received wide surgical margins (p = 0.047 and p = 0.019, respectively). Those who underwent hindquarter amputation were more likely to achieve wide margins (p = 0.05). Time to recurrent disease (local or systemic) was always less than 24 months. No hindquarter amputation for recurrent disease resulted in disease-free survival. No patient who received adjuvant therapy for palliative or recurrent disease had disease control. CONCLUSIONS: Pelvic dedifferentiated CS often presents at an advanced local or systemic stage and confers a poor prognosis. Achieving wide surgical margins (> 4 mm) provided the highest rate of long-term disease-free survival. Failing to achieve wide margins results in rapid disease recurrence, conferring deleterious consequences.
format Online
Article
Text
id pubmed-6293503
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62935032018-12-17 Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment Lex, Johnathan R. Evans, Scott Stevenson, Jonathan D. Parry, Michael Jeys, Lee M. Grimer, Robert J. Clin Sarcoma Res Research BACKGROUND: Dedifferentiated chondrosarcomas (CS) are a high-grade variant of CS that confers a 5-year survival of around 10–24%. Dedifferentiated CS arising from the pelvis confers an even worse prognosis. QUESTIONS: (1) What is the prognosis of patients with dedifferentiated CS of the pelvis? (2) Do wide margins or type of surgical intervention influence outcome? (3) Does the use of adjuvant therapy affect outcome? METHODS: Patients were retrospectively reviewed from a prospectively collated musculoskeletal oncology database from 1995 to 2016. Thirty-one cases of dedifferentiated CS arising from the pelvis were included. Wide margins were defined as greater than 4 mm. The mean age was 55.6 years (range 33 to 76 years) and there were 19 males (61.3%) and 12 females (38.7%). RESULTS: The disease presented at a locally or systemically advanced stage in 13 patients (41.9%). Eighteen patients (58.1%) underwent surgery with curative intent. Overall survival at 12 months was 15.4% for patients treated with palliative intent and 50% for those treated with surgery. In the surgical group, there were higher rates of disease-free survival in patients who underwent hindquarter amputation and those who received wide surgical margins (p = 0.047 and p = 0.019, respectively). Those who underwent hindquarter amputation were more likely to achieve wide margins (p = 0.05). Time to recurrent disease (local or systemic) was always less than 24 months. No hindquarter amputation for recurrent disease resulted in disease-free survival. No patient who received adjuvant therapy for palliative or recurrent disease had disease control. CONCLUSIONS: Pelvic dedifferentiated CS often presents at an advanced local or systemic stage and confers a poor prognosis. Achieving wide surgical margins (> 4 mm) provided the highest rate of long-term disease-free survival. Failing to achieve wide margins results in rapid disease recurrence, conferring deleterious consequences. BioMed Central 2018-12-14 /pmc/articles/PMC6293503/ /pubmed/30559960 http://dx.doi.org/10.1186/s13569-018-0110-1 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lex, Johnathan R.
Evans, Scott
Stevenson, Jonathan D.
Parry, Michael
Jeys, Lee M.
Grimer, Robert J.
Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment
title Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment
title_full Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment
title_fullStr Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment
title_full_unstemmed Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment
title_short Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment
title_sort dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293503/
https://www.ncbi.nlm.nih.gov/pubmed/30559960
http://dx.doi.org/10.1186/s13569-018-0110-1
work_keys_str_mv AT lexjohnathanr dedifferentiatedchondrosarcomaofthepelvisclinicaloutcomesandcurrenttreatment
AT evansscott dedifferentiatedchondrosarcomaofthepelvisclinicaloutcomesandcurrenttreatment
AT stevensonjonathand dedifferentiatedchondrosarcomaofthepelvisclinicaloutcomesandcurrenttreatment
AT parrymichael dedifferentiatedchondrosarcomaofthepelvisclinicaloutcomesandcurrenttreatment
AT jeysleem dedifferentiatedchondrosarcomaofthepelvisclinicaloutcomesandcurrenttreatment
AT grimerrobertj dedifferentiatedchondrosarcomaofthepelvisclinicaloutcomesandcurrenttreatment